Navigation Links
Human Genome Sciences Announces Presentation at AASLD of Results of Phase 2b Trial of Albuferon(R) for Chronic Hepatitis C
Date:11/5/2007

1200 Q4w

treatment group achieved SVR, vs. 57.9% for peginterferon alfa-2a

administered every week.

-- In heavier patients (75 kg or heavier) who were treatment-adherent,

61.0% of those in the Albuferon 1200 Q4w treatment group achieved SVR,

versus 53.3% for peginterferon alfa-2a administered once every week.

-- Among all treatment-adherent patients in the Albuferon 1200 Q4w

treatment group, 62.0% achieved SVR, versus 66.7% for peginterferon

alfa-2a.

-- The rate of discontinuations due to adverse events was 12.1% in the

Albuferon 1200 Q4w treatment group, vs. 6.1% in the peginterferon alfa-

2a group. Adverse events observed were those typically expected with

interferon therapy.

-- The number of patients experiencing severe hematologic adverse events

was significantly lower in the Albuferon 1200 Q4w treatment group

(10.3%, vs. 20.2% for peginterferon alfa-2a, p<0.05).

Higher doses of Albuferon administered every four weeks, in combination with ribavirin, will be explored in a separate Phase 2b trial conducted by Novartis, which is expected to begin by year-end 2007.

About Albuferon

Albuferon is a novel long-acting form of interferon alpha created by HGS using its proprietary albumin fusion technology. Albuferon results from the genetic fusion of human albumin and interferon alpha. Human albumin is the most prevalent naturally occurring blood protein in the human circulatory system, persisting in circulation in the body for more than 20 days. Research shows that genetic fusion of therapeutic proteins to human albumin decreases clearance and prolongs the half-life of the proteins. Recombinant interferon alpha is approved for the treatment of hepatitis C, hepatitis B and a number of cancers.

Albuferon is being developed by HGS and Novartis for the treatment of chronic hepatitis C under a worldwide co-development and commerci
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Video: New Research Discovers Independent Brain Networks Control Human Walking
2. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
3. Enrollment Begins on Human PK Study for Medidur(TM) FA
4. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
5. Study Confirms Limited Human-To-Human Spread of Avian-Flu Virus in Indonesia in 2006
6. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
7. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
8. Dr. Roger Kenneth Hershline PhD MD, CEO of Global Humanceuticals, Inc. Donates New HIV Drug
9. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
10. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
11. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Oct. 21, 2014   BioNano Genomics , ... genomics research centers to purchase an Irys™ System ... National Cancer Institute (NCI), NIH Intramural Sequencing Center (NISC) ... Irys, obtaining a comprehensive view of a genome ... (NGS) does not deliver the scalability or reliability ...
(Date:10/22/2014)... 21, 2014 Abaxis, Inc. (NasdaqGS: ... analysis systems, today reported financial results for the second ... quarter overview: , Revenues of $53.9 million, up ... EPS of $0.24, up 33% over last year,s comparable ... from Abaxis Veterinary Reference Laboratories (AVRL) of $3.5 million, ...
(Date:10/22/2014)... WESTMINSTER, Colo. , Oct. 22, 2014   ... class of infusion systems designed to maximize targeted delivery ... is pleased to announce that oncologist John R. ... Norris Comprehensive Cancer Center, and surgical oncologist Steven ... Center have joined the Company,s Scientific Advisory Board (SAB).  ...
Breaking Medicine Technology:BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 2BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 3Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 2Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 3Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 4Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 5Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 6Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 7Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 8Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 9Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 10Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 11Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 12Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 13Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 14Surefire Medical's Scientific Advisory Board Expands, Broadens Clinical Trial Expertise 2
... Inhibitor-, SOUTH SAN FRANCISCO, Calif., Jan. 7 ... has initiated a phase 1/2 trial,of XL184 in patients ... disease while on a regimen containing erlotinib., XL184 ... RET and,VEGFR receptor tyrosine kinases. In the initial phase ...
... scientists today,report that the genetic variant on chromosome ... of heart attack is also associated with up ... (AAA) and intracranial,aneurysm (IA). This is the first ... condition. The paper, entitled ,The same sequence,variant on ...
Cached Medicine Technology:Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer 2Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer 3Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer 4Not Only Lipids and Inflammation: Insight Into a New Cause of Heart Attack and Other Vascular Disease 2Not Only Lipids and Inflammation: Insight Into a New Cause of Heart Attack and Other Vascular Disease 3
(Date:10/22/2014)... Mission Viejo, CA (PRWEB) October 22, 2014 ... that Jay Cormier, Sr. Vice President of Sales, will ... at the upcoming Meetings Technology Expo on October 28, ... will also be hosting a booth as well as ... on how Lintelus Meeting can create a more engaging ...
(Date:10/22/2014)... By Maureen Salamon ... -- Black women undergoing in vitro fertilization (IVF) are only ... using the popular assisted reproduction technique, new research indicates, and ... In the study, about 31 percent of white patients ... black patients. Analyzing more than 4,000 IVF cycles over ...
(Date:10/22/2014)... Measures taken by Firestone officials at the company,s ... the spread of the disease there and could prove ... Co. provides health services to about 80,000 employees, retirees, ... Between Aug. 1 and Sept. 23, there were ... people. That incidence rate of 0.09 percent was much ...
(Date:10/20/2014)... 2014 With a mere 19 days ... made a brief fundraising stop at the  Law ... Fresh from a debate last night with his opponent ... for the first seven minutes because Crist had an ... the incident in one word: "weird." , Before touching ...
(Date:10/20/2014)... Women’s health specialist, Dr. Amber Murphy, MD, Ob/Gyn ... Inc., A Division of MaternOhio Clinical Associates, Inc., who ... patients annually. Dr. Murphy will provide a full range ... women’s life. She is accepting new patients at two ... , Dr. Murphy offers a wide variety of services ...
Breaking Medicine News(10 mins):Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3Health News:Tire Company Sets Standard for Ebola Care in Liberia: CDC 2Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 2Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 3Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 2Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 3
... (HealthDay News) -- Feelings of shame, social isolation and rejection ... finds. The findings may help explain why depression is ... other kinds of cancer, according to the researchers at the ... association with tobacco use, lung cancer is commonly viewed as ...
... a key mechanism that causes breast cancer to spread. The ... journal Molecular Cell , enhances our knowledge about the ... for a lethal form of invasive breast cancer that is ... ErbB2 has been linked with aggressive forms of breast cancer ...
... irritable bowel syndrome (IBS) have a significantly greater prevalence ... as well as physical, emotional and sexual abuse, according ... Hepatology, the official journal of the American Gastroenterological ... associated with the development of irritable bowel syndrome, particularly ...
... most common kidney cancer subtype, face a low risk of ... key findings of a multi-centre study of nearly 600 patients ... BJUI . "Because papillary renal cell ... patients, the small number of patients enrolled in individual studies ...
... strategy includes a plan to ensure that General Practitioners (GPs) ... 23 March 2012, downloadable from http://www.homeoffice.gov.uk/publications/ ). There is ... The big question is, what should GPs say to their ... scientific journal Addiction analysed the advice given by ...
... PHILADELPHIA Patients with end-stage liver disease complicated by ... carcinoma (HCC) are less likely to die or ... a new liver than those with other complications of ... Perelman School of Medicine at the University of Pennsylvania. ...
Cached Medicine News:Health News:Stigma, Shame Can Worsen Depression in Lung Cancer Patients 2Health News:Researchers identify mechanism that makes breast cancer invasive 2Health News:Childhood traumatic experiences associated with adult IBS symptoms 2Health News:Kidney cancer subtype study finds low recurrence and cancer death rates 2Health News:Penn researchers call for a re-examination of transplant waitlist prioritization 2Health News:Penn researchers call for a re-examination of transplant waitlist prioritization 3
... Wrist Fixator is now available in a ... necessary instrumentation. The surgical technique is printed ... reference. , ,This fixator allows the surgeon ... making multipaner adjustments in the frame via ...
... The WristJack External Fixation System for ... palmar tilt, radial inclination, length and rotation. ... to place the wrist into extension without ... are easily performed in the surgeons office. ...
... slender design contributes to overall low-profile frame ... The Connecting Clamp allows connection of 3.0 ... Uses 3.0 mm Carbon Fiber Rods. The ... to predrill and provide more stability and ...
The DFS MiniFixator is a lightweight, external device for the treatment of small bone fractures and osteotomies....
Medicine Products: